Benzeneacetic acid, 4-[[2-(3-chlorophenyl)-6-(trifluoromethyl)-4-pyridinyl]methyl]- manufacturers
- Zatolmilast
-
- $64.00
-
2026-07-14
- CAS:1606974-33-7
- Purity: 99.31%
- Supply Ability: 10g
- Zatolmilast
-
- $64.00
-
2026-07-14
- CAS:1606974-33-7
- Purity: 99.31%
- Supply Ability: 10g
- BPN14770
-
- $1.00
-
2025-09-01
- CAS:1606974-33-7
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 20T
|
| | Benzeneacetic acid, 4-[[2-(3-chlorophenyl)-6-(trifluoromethyl)-4-pyridinyl]methyl]- Basic information |
| | Benzeneacetic acid, 4-[[2-(3-chlorophenyl)-6-(trifluoromethyl)-4-pyridinyl]methyl]- Chemical Properties |
| Boiling point | 514.4±50.0 °C(Predicted) | | density | 1.351±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 260 mg/mL (640.71 mM) | | pka | 4.27±0.10(Predicted) | | form | Solid | | color | White to off-white |
| | Benzeneacetic acid, 4-[[2-(3-chlorophenyl)-6-(trifluoromethyl)-4-pyridinyl]methyl]- Usage And Synthesis |
| Uses | Zatolmilast is a selective phosphodiesterase 4D (PDE4D) allosteric inhibitor for the treatment of fragile X syndrome and other brain disorders. | | in vivo | Zatolmilast increases brain cAMP, increases phosphorylation of CREB and increases production of brain-derived neurotrophic factor (BDNF) in hippocampus[1].
Zatolmilast (0.1-30 mg/kg; p.o.; 24 hours) provides cognitive benefit in the mouse novel object recognition (NOR) at doses above 0.3 mg/kg[2]. | Animal Model: | C57Bl6 mice[2] | | Dosage: | 0.1, 0.3, 1, 3, 10, 30 mg/kg | | Administration: | p.o.; 24hours | | Result: | Significantly improved novel object discrimination at doses above 0.3 mg/kg. |
| | IC 50 | PDE4D3: 7.4 nM (IC50); PDE4D7: 7.8 nM (IC50) |
| | Benzeneacetic acid, 4-[[2-(3-chlorophenyl)-6-(trifluoromethyl)-4-pyridinyl]methyl]- Preparation Products And Raw materials |
|